PHAXIAM THERAPEUTICS S.A. PHAXIAM Therapeutics S.A. Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.998 EUR | -0.10% |
|
+0.40% | -53.00% |
| 07-03 | Phaxiam: EPIC Bpifrance exceeds 25% of share capital | CF |
| 06-28 | Would you like some more inflation? |  |
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
24/09/2024
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.998
EUR
Average target price
5.1
EUR
Spread / Average Target
+155.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -53.00% | 21.79M | |
| +20.17% | 127B | |
| +24.67% | 117B | |
| +25.44% | 27.67B | |
| -17.74% | 20.33B | |
| -15.17% | 16.79B | |
| -15.21% | 15.63B | |
| +11.91% | 14.84B | |
| -47.10% | 14.65B | |
| +54.50% | 14.43B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
- News PHAXIAM Therapeutics S.A.
- Bank Stocks Buoy European Equities in Tuesday Trading
